NEW YORK (GenomeWeb News) – OncoMed Pharmaceuticals and Fluidigm have entered into a collaboration to use microfluidic tools to analyze the heterogeneity of tumor cells, including cancer stem cells, the companies said yesterday.

The partnership will combine Fluidigm's microfluidic platforms with OncoMed's cancer stem cell sorting technology to generate tools to analyze, quantify and develop treatments directed at a highly tumorigenic cell population, the companies said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.